AUBREY FORD: Open Payments
NPI 1952015273 · PROVO, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$708 in 37 payments from 14 companies in 2025. Trend: 2023 $511 · 2024 $427 · 2025 $708
Food & beverage: $708
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $287 |
| AstraZeneca Pharmaceuticals LP | 3 | $69 |
| Novo Nordisk Inc | 3 | $55 |
| Lilly USA, LLC | 3 | $44 |
| Neurocrine BioSciences, Inc. | 2 | $41 |
| PFIZER INC. | 2 | $38 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $33 |
| bioMerieux Inc | 1 | $28 |
| Corcept Therapeutics | 1 | $22 |
| SANOFI-AVENTIS U.S. LLC | 1 | $21 |
Products named: VRAYLAR, AIRSUPRA, UBRELVY, Wegovy, QULIPTA, MOUNJARO, INGREZZA, PREVNAR 20.
Industry payments across UT — which companies pay providers there.
